Navigation Links
QRxPharma Begins Trading on the International OTCQX
Date:7/1/2008

Strategy to Expand US Investor Base and Increase International Liquidity

SYDNEY, Australia and BEDMINSTER, N.J., July 1 /PRNewswire/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today its recently initiated Level 1 American Depositary Receipt (ADR) program has been listed on the International OTCQX. QRxPharma's ADR began trading yesterday, June 30 on International PrimeQX under the ticker QRXPY.

The International OTCQX is the leading electronic trading, quotation and disclosure venue to the U.S. over-the-counter (OTC) market. The International OTCQX provides issuers with an efficient and robust platform on which to list securities and access some of the deepest pools of liquidity in the world. The listing of the ADR program on the International OTCQX will enable QRxPharma shares to be more accessible to U.S. institutions and private investors, including those permitted to buy only US-based securities, and distinguishes the QRxPharma ADR program from the approximately 8,000 OTC securities currently traded in the U.S.

"As QRxPharma prepares to initiate final Phase 3 studies of its lead dual-opioid product candidate, Q8003IR, for NDA submission to the FDA in 2009, we are working proactively to diversify and extend our shareholder base" said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "With the Company achieving its critical development milestones as projected and reporting positive clinical data to date, this initiative is part of a broad strategy to maximize value, provide access to U.S. investors, and increase international liquidity."

U.S. investment bank Merriman Curhan Ford, will serve as QRxPharma's Principal American Liaison ("PAL") on the International OTCQX, responsible for providing guidance on listing requirements.

"I congratulate QRxPharma for listing on the International OTCQX -- the first step to gaining access to the U.S. institutional investor base" said Stephen Nash, Managing Director and Head of OTCQX Advisory at Merriman Curhan Ford. "We are proud to be QRxPharma's Principal American Liaison, by providing the Company with value-added U.S. capital markets services that complement its OTCQX listing, such as introductions to sell-side equity research analysts, institutional investor road shows and speaking opportunities at Merriman's investor conferences. Since early 2007, the OTCQX has grown to represent more than $425 billion in market capitalization of quality companies listed on the platform without the added costs of SEC registration and Sarbanes-Oxley compliance."

JP Morgan Chase Bank operates the ADR program and acts as the Depositary Bank. In accordance with normal ADR practice, shares will be consolidated into larger value parcels with each ADR representing 5 ordinary QRxPharma shares.

"With QRxPharma's listing on the International OTCQX, we now have a wide range of opportunities available to the Company to advance early-stage clinical programs and aggressively pursue our commercialization strategy for Q8003IR," said Holaday.

QRxPharma completed an underwritten initial public offering under the symbol "QRX" on the Australian Securities Exchange (ASX) on May 25, 2007. The A$50 million IPO was one of the largest life science offerings in Australia.

For more information please contact John Holaday - Managing Director and Chief Executive Officer, Tel: +1 301 908 3086, Email: john.holaday@qrxpharma.com, or Chris J Campbell - Chief Financial Officer and Company Secretary, Tel: +61 2 9492 8021, Email: chris.campbell@qrxpharma.com.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates

with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialize its products in the U.S. and seek strategic partnerships abroad. QRxPharma's lead compound, Q8003IR, successfully completed initial Phase 3 studies, meeting primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: http://www.QRxPharma.com.

About Merriman Curhan Ford

Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on fast-growing companies and the institutions who invest in them. The company offers high-quality investment banking, equity research, institutional services, primary market research, asset management and corporate & venture services, and specializes in four growth industry sectors: CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. For more information, please go to http://www.mcfco.com.

About International OTCQX

International OTCQX provides a gateway to U.S. securities markets for international companies that are listed on a qualified non U.S. exchange and provide ongoing disclosure in English to U.S. investors. More importantly, International OTCQX distinguishes the reputable international issuers from the 8,000 over-the-counter (OTC) securities traded in the U.S. Only leading companies that have substantial operating businesses and provide credible disclosure to the public are eligible for inclusion on the premium-tier International OTCQX, which commenced trading on March 5, 2007. For more about International OTCQX, visit http://www.otcqx.com.


'/>"/>
SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
2. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
3. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
4. Natural Nutrition Begins Exports of InterACTIVE Nutrition Brand Products to Pakistan
5. Fred Hutchinson Cancer Research Centers Inaugural Big Expedition for Cancer Research Begins in Alaska
6. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
7. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
8. VA Begins Next Phase of Combat Vet Outreach
9. Institute for Integrative Nutrition Begins Road Tour
10. Alabama Begins Mandatory Screening of Newborns for Cystic Fibrosis
11. The Montreal Childrens Hospital of the MUHC begins search for causes of autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: